Characterization of sirolimus metabolites in pediatric solid organ transplant recipients

Pediatric Transplantation

Volumn 13, Issue 1, 2009, Pages 44-53

  Filler, Guido ^b   Bendrick Peart, Jamie ^a   Strom, Tobin ^a   Zhang, Yan Ling ^a   Johnson, Gillian ^a   Christians, Uwe ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Age dependent; Blood metabolite patterns; Children; Pharmacokinetics; Sirolimus

Indexed keywords

12 HYDROXYSIROLIMUS; 16 O DESMETHYL SIROLIMUS; 24 HYDROXYSIROLIMUS; 39 O DESMETHYL SIROLIMUS; 46 HYDROXYSIROLIMUS; DIHYDROXYSIROLIMUS; DRUG METABOLITE; PIPERIDINE HYDROXYSIROLIMUS; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE;

AREA UNDER CURVE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; SIROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 58149312777     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00956.x     Document Type: Article

References (24)

1. Morris RE. Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992 : 6 : 39 87.
2. Hodges CB, Maxwell H, Beattie TJ, Murphy AV, Jindal RM. Use of rapamycin in a transplant patient who developed cyclosporine neurotoxicity. Pediatr Nephrol 2001 : 16 : 777 778.
3. Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004 : 8 : 171 177.
4. Bai S, Stepkowski SM, Kahan BD, Brunner LJ. Metabolic interaction between cyclosporine and sirolimus. Transplantation 2004 : 77 : 1507 1512.
5. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 2005 : 9 : 520 522.
6. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004 : 43 : 83 95.
7. Wilson D, Johnston F, Holt D, et al. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. Clin Biochem 2006 : 39 : 378 386.
8. Morris RG, Salm P, Taylor PJ, Wicks FA, Theodossi A. Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients. Ther Drug Monit 2006 : 28 : 164 168.
9. Jones K, Saadat-Lajevard S, Lee T, et al. An immunoassay for the measurement of sirolimus. Clin Ther 2000 : 22 : B49 B61.
10. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992 : 20 : 186 191.
11. Streit F, Christians U, Schiebel HM, Meyer A, Sewing KF. Structural identification of four metabolites of the macrolide immunosuppressant sirolimus after in vitro metabolism by electrospray-MS/MS. Drug Metab Dispos 1996 : 24 : 1272 1278.
12. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 1996 : 42 : 1417 1425.
13. Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001 : 33 : 514 515.
14. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - Drug disposition, action, and therapy in infants and children. N Engl J Med 2003 : 349 : 1157 1167.
15. Filler G, Womiloju T, Feber J, Lepage N, Christians U. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005 : 5 : 2005 2010.
16. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit 2005 : 27 : 770 778.
17. Müller C, Schäfer P, Störtzel M, Vogt S, Weinmann W. Ion suppression effects in liquid chromatography-electrospray-ionization transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J Chromatogr B 2002 : 773 : 47 52.
18. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants. J Chromatogr B Biomed Sci Appl 2000 : 748 : 41 53.
19. Boernsen KO, Egge-Jacobsen W, Inverardi B, et al. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom 2007 : 42 : 793 802.
20. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000 : 22 : B101 B121.
21. Holt DW, McKeown DA, Lee TD, Hicks D, Cal P, Johnston A. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant Proc 2004 : 36 : 3223 3225.
22. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P4503A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992 : 20 : 753 761.
23. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Exp Pharmacol Ther 1998 : 285 : 1104 1112.
24. Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 1997 : 61 : 2567 2574.